Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Audit Slows Down Medtronic Launch Plans For Low-Glucose-Suspend Diabetes System

This article was originally published in The Gray Sheet

Executive Summary

A recent FDA inspection of Medtronic’s diabetes business identified quality systems deficiencies that are likely to delay the firm’s launch of its first-of-a-kind MiniMed 530G insulin pump/continuous glucose monitoring system.

You may also be interested in...



Medtronic Sees Long-Awaited Approval Of MiniMed 530G As A Big Step In Artificial Pancreas “Journey”

Medtronic recently announced FDA approval of its MiniMed 530G low-glucose-suspend insulin pump, the first system approved in the U.S. that can automatically stop insulin delivery when blood glucose levels fall to a pre-set level.

News Briefs: Medtronic’s First-Gen Artificial Pancreas Approved; CMS Removes Bariatric Surgery Requirements

FDA approves Medtronic’s MiniMed 530G system, making it the first system in the U.S. that can automatically suspend insulin delivery to people with diabetes. CMS removes bariatric surgery facility certification requirements. More news.

Medtronic Signals More To Come On Its Pivot To Hospital Services

The company’s leadership team is “determined to transform Medtronic from being a primarily device provider today into the premier global medical technology solutions partner of tomorrow,” CEO Omar Ishrak said.

Related Content

Topics

UsernamePublicRestriction

Register

MT032088

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel